Tempest Therapeutics (TPST): Operatsion rentabellik

Ommaviy kompaniya Tempest Therapeutics Inc (TPST) logotipi

Kimyoviy sintez patentlari tufayli kirishning yuqori to'siqlari Tempest Therapeutics (TPST) kompaniyasini generik dori vositalaridan himoya qiladi, bu esa GURU.Markets grafigidagi operatsion marja tendentsiyasi bilan tasdiqlanadi, u yerda joriy ko'rsatkich 0.00 ni tashkil etadi. Boshqaruvning kapital jalb qilishdagi tajribasi poydevorni mustahkamlaydi, garchi onkologik dori vositalariga tor ixtisoslashuv klinik sinovlar natijalariga bog'liqlikning binariy xavfini tug'dirsa-da.

TPST - Tempest Therapeutics Inc Operatsion foyda koeffitsiyenti 04.07.2022 - 19.11.2026 oraligʻida

Tempest Therapeutics (TPST) moliyaviy va bozor koʻrsatkichlari kesimi

- aksiya narxi va baholash bo'yicha konsensus prognoz:
Kompaniyaning fundamental baholanishi:tempesttx.com, TPST
Tempest Therapeutics Corp brendining mahsuloti

Operatsion marja trekkeri Tempest Therapeutics (TPST) kompaniyasining operatsion samaradorligini vizuallashtiradi, bu ko'rsatkich foizlar va soliqlar to'lanishidan oldingi foydaning umumiy daromadga nisbati sifatida ifodalanadi. Ushbu ko'rsatkich sog'liqni saqlash gigantining onkologik dori vositalarining klinik sinovlari bilan bog'liq xarajatlarni nazorat qilish qobiliyatini baholash imkonini beradi, bunda barqaror yoki o'sib borayotgan daromadlilik aktivlarning moliyaviy barqarorligini va potentsial xaridorlar uchun ularning investitsiya jozibadorligini tasdiqlaydi.

Tempest Therapeutics raqobatchilari

Operatsion rentabellik BeiGene Ltd|Halozyme Therapeutics - Operatsion foyda marjasi|Sotuvning operatsion marjasi RVMD (Revolution Medicines Corp)|Operatsion foyda koeffitsiyenti AAPG|Operatsion rentabellik CG Oncology Therapeutics CGON|Operatsion foyda normasi URGN|BCAX: Sotuvning operatsion marjasi|PSNL: Operatsion rentabellik|Erasca (ERAS) - Operatsion rentabellik|DCTH - Operatsion faoliyat rentabelligi|YMAB (Y-mAbs Corp) - Operatsion marja|Sotuvning operatsion marjasi Aura Biosciences (AURA)|Operatsion rentabellik Candel Therapeutics Inc. (CADL)|Sotuvning operatsion marjasi Accuray, Inc. ARAY|Operatsion rentabellik sellaslifesciences.com SLS|Operatsion foyda normasi ACTU|CTOR - Operatsion rentabellik|Operatsion faoliyat rentabelligi tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operatsion rentabellik|FATE: Operatsion foyda koeffitsiyenti|WHWK (Aadi Bioscience, Inc.) - Operatsion marja|TCRX (TScan Therapeutics) - Operatsion foyda koeffitsiyenti|Operatsion rentabellik Champions Oncology (CSBR)|Operatsion faoliyat rentabelligi XBiotech USA|Operatsion rentabellik CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Sotuvning operatsion rentabelligi|RADX - Operatsion rentabellik|ARTV - Operatsion marja|Adlai Nortye Ltd (ANL) - Operatsion rentabellik|Veru Pharma - Operatsion foyda normasi|Operatsion rentabellik Xilio Therapeutics|Operatsion foyda bo'yicha sotuv rentabelligi RENB (Renovaro Inc.)|Operatsion rentabellik Mural Oncology PLC (MURA)|Operatsion marja Kairos Pharma (KAPA)|Operatsion rentabellik onkuretherapeutics.com OKUR|GDTC: Operatsion foyda bo'yicha sotuv rentabelligi|CRIS: Sotuvning operatsion marjasi|apollomicsinc.com (APLM) - Sotuvning operatsion marjasi|THAR: Operatsion marja|Sotuvning operatsion marjasi Advanced Biomed Inc.|Sotuvning operatsion marjasi GNPX|Operatsion foyda bo'yicha sotuv rentabelligi CLDI (Calidi Biotherapeutics)|Operatsion marja SBFM|Xenetic Biosciences, Inc. - Operatsion foyda bo'yicha sotuv rentabelligi|Operatsion rentabellik Salarius Pharmaceuticals SLRX|Operatsion marja purple-biotech.com PPBT|AONC - Operatsion rentabellik|BGNE: Operatsion rentabellik|CKPT: Operatsion marja|Elevation Oncology - Operatsion foyda normasi|ICAD (iCAD) - Operatsion marja|IKNA: Operatsion foyda normasi|Operatsion rentabellik Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operatsion foyda normasi|Operatsion rentabellik MorphoSys Corporation MOR|NAYA: Operatsion foyda bo'yicha sotuv rentabelligi|Ascentage Pharma Group International - Operatsion marja